ASP Isotopes (ASPI) Canaccord Genuity's 46th Annual Growth Conference summary
Event summary combining transcript, slides, and related documents.
Canaccord Genuity's 46th Annual Growth Conference summary
12 Aug, 2026Strategic focus and business structure
Operations span electronics, nuclear medicine, and nuclear fuels, with three production facilities in South Africa and recent acquisitions in the U.S.
PET Labs is the largest producer of Fluorine-18 radionuclides in South Africa, with expansion plans in the U.S. and Europe.
Renergen manages helium and LNG production, with the Virginia Gas Project set to begin helium output by September and a major expansion planned.
Quantum Leap Energy is developing nuclear fuel technologies and is being spun out to focus on the nuclear fuel cycle.
The company is vertically integrated in stable and radioactive isotope production, enhancing supply chain security and margins.
Technology and production capabilities
Utilizes proprietary Aerodynamic Separation Process for gaseous isotopes and Quantum Enrichment (laser-based) for metals.
Modular plant design allows flexible scaling and lower capital expenditure compared to traditional centrifuges.
Silicon-28 production targets both quantum computing (high purity) and semiconductor (lower purity, higher volume) markets.
Helium is critical for semiconductors and medical devices, with supply chain disruptions creating market opportunities.
Commercial deliveries for Silicon-28, Carbon-14, and Ytterbium-176 are targeted for the second half of 2026.
Market dynamics and expansion plans
Global isotope supply chains are compromised, with most production in Russia; Western customers seek alternatives.
PET Labs' revenue growth is driven by investments in production capacity and rising demand for PET and SPECT isotopes.
U.S. radiopharmacy acquisitions will be upgraded to produce PET isotopes, with further expansion opportunities identified.
Helium market faces shortages due to Middle East disruptions; strategic reserves are depleting, likely driving prices higher.
Contracts signed for 15% of phase I helium capacity, with more negotiations ongoing as demand is expected to rise.
Latest events from ASP Isotopes
- Quarterly revenue grew to $5.1M, net loss narrowed, and Renergen acquisition expanded operations.ASPI
Q2 2026 - Phase I helium shipments begin September, with major expansion and strong contracts driving growth.ASPI
Investor update - Advancing isotope enrichment for semiconductors, medicine, and energy with 2026 milestones.ASPI
Corporate presentation - Expanding isotope enrichment and supply to critical markets with strong growth targets.ASPI
Corporate presentation - Q1 2026 revenue grew to $4.2M, but net loss widened to $26.7M amid expansion and integration costs.ASPI
Q1 2026 - Advancing isotope enrichment and supply to meet global demand in critical high-value markets.ASPI
Corporate presentation - 2026 brings first isotope and helium shipments, $23.8M revenue, and >$300M EBITDA target.ASPI
Q4 2025 - Helium and isotope production ramp up amid global shortages, with major commercialization by 2026.ASPI
2nd Annual CG Virtual Sustainability Summit - Commercial production ramped up across three plants, with strong cash reserves and growth outlook.ASPI
Q4 2024